Edwards Lifesciences Rallies After U.S. Proposal Expands TAVR Coverage
Edwards Lifesciences shares climbed 3.6% on Tuesday after the U.S. government published a proposed National Coverage Decision that would broaden coverage for transcatheter aortic-valve replacement (TAVR). Key changes in the memo include coverage for asymptomatic severe aortic stenosis under coverage with evidence development, removal of the dual-op…